Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — 9M 2024 Earnings Presentation
11 slides from Eurofins Scientific's earnings presentation, Oct 22, 2024
Slide 1: 9M 2024 Trading Update
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2024. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Key financial and operational highlights
Key financial and operational highlights Reported Revenues Key Highlights • Reported revenues in 9M 2024 reached €5,142m, +6.7% vs 9M 2023, supported by organic 9M 2024 Q3 2024 growth2 in the Core Business1 but restrained by FX headwinds (-0.5%). • Organic revenue growth2 in the Core Business (exclu
Slide 4: Revenue bridge
Revenue bridge (€m) 5,142 9M 2024: +5.2%1 H1 2024: +5.6%1 • FX headwind of 0.5% due to strength Q3 2024: +4.4%1 of the Euro against the US Dollar and numerous Asian currencies • Organic revenue growth in the Core Business1 was 5.2% in 9M 2024 and 4.4% in Q3 2024 • The pace of acquisitions has 4,858
Slide 5: 2024 profitability and cash flow objectives confirmed
2024 profitability and cash flow objectives confirmed (€m) FY 2024 Mid-term objectives FY 2027 Revenues Close to €7bn +6.5% organic growth p.a. Approaching €10bn (Previously €7.075bn – €7.175bn) €250m revenues added from M&A p.a. €1.525bn – €1.575bn Continued growth investments in: Adj.1 EBITDA1 (Ma
Slide 6: Q&A
Q&A CONFIDENTIAL CONFIDENTIAL AND -PROPRIETARY AND PROPRIETARY - © Eurofins © Eurofins Scientific (Ireland) Scientific Ltd [2024]. (Ireland) All rights reserved. AnyLtd 2021. use of All rights this material reserved. without the specific Any use of permission ofanthis material authorized without the
Slide 7: Appendix
Appendix CONFIDENTIAL CONFIDENTIAL AND -PROPRIETARY AND PROPRIETARY - © Eurofins © Eurofins Scientific (Ireland) Scientific Ltd [2024]. (Ireland) All rights reserved. AnyLtd 2021. use of All rights this material reserved. without the specific Any use of permission ofanthis material authorized withou
Slide 8: Revenue by activity in 9M 2024
Revenue by activity in 9M 2024 Q3 2023: +6.6%1 Q2 2023: +7.5%1 Activities are defined as follows: €523m • Life: • Food and Feed Testing • Agro Testing • Environment Testing €1,025m €2,093m • BioPharma: • BioPharma Services • Agrosciences • Genomics • Forensic Services • Diagnostic Services & Product
Slide 9: Revenue by Operating Segment
Revenue by Operating Segment Organic growth Y-o-Y variation €m 9M 2024 As % of total 9M 2023 As % of total in the Core % Business1 Europe 2,620 51% 2,435 51% +7.6% +5.4% North America 1,974 38% 1,870 39% +5.6% +3.9% Rest of the World 547 11% 515 11% +6.2% +8.6% Total 5,142 100% 4,821 100% +6.7% +5.2
Slide 10: Revenue by Area of activity
Revenue by Area of activity Y-o-Y variation Organic growth in €m 9M 2024 As % of total 9M 2023 As % of total % the Core Business1 Life 2,093 41% 1,904 39% +9.9% +7.6% BioPharma 1,501 29% 1,473 31% +1.9% +1.6% Diagnostic Services & Products 1,025 20% 958 20% +6.9% +4.3% Consumer & Technology Products
Slide 11: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) APMs used in this presentation Adjusted results – reflect the ongoing performance of the mature and recurring activities excluding “separately disclosed items”. Separately disclosed items (SDI) – include: • one-off costs from integration and reor